Free radicals and antioxidants in cardiovascular diseases

References

• Gharavi A, Lifton RP. The inherited basis of blood pressure variation and hypertension. In: The Metabolic and Molecular Bases of Inherited Diseases, Volume 4. Scriver CR, Beaudet AL, Sly WS, Valle D (Eds). McGraw-Hill, New York, USA, 5399–5418 (2001).
   Google Scholar
• Lüscher TF, Noll G. The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis118(Suppl.), S81–S90 (1995).
   PubMedGoogle Scholar
• Linder L, Kiowski W, Bühler FR, Lüscher TF. Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation81, 1762–1767 (1990).
   PubMed Web of Science ®Google Scholar
• Panza JA, Quyyumi AA, Brush JJ, Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with esssential hypertension. N. Engl. J. Med.323, 22–27 (1990).
   PubMed Web of Science ®Google Scholar
• Lüscher TF. Imbalance of endothelium-derived relaxing and contracting factors: a new concept in hypertension? Am. J. Hypertens.317, 317–330 (1990).
   Google Scholar
• Sagripanti A, Carpi A. Antithrombotic and prothrombotic activities of the vascular endothelium. Biomed. Pharmacother.54, 107–111 (2000).
   PubMed Web of Science ®Google Scholar
• Golino P, Ragni M, Cirillo P et al. Effects of tissue factor induced by oxygen free radicals on coronary flow during reperfusion. Nature Med.2, 35–40 (1996).
   PubMed Web of Science ®Google Scholar
• Sase K, Michel T. Expression and regulation of endothelial nitric oxide synthase. Trends Cardiovasc. Med.7, 28–37 (1997).
   PubMed Web of Science ®Google Scholar
• Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N. Engl. J. Med.323, 27–36 (1990).
   PubMed Web of Science ®Google Scholar
• Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. J. Am. Med. Assoc.282, 2035–2042 (1999).
   PubMed Web of Science ®Google Scholar
• Spieker LE, Noll G, Ruschitzka FT, Lüscher TF. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future? J. Am. Coll. Cardiol.37, 1493–1505 (2001).
   PubMed Web of Science ®Google Scholar
• Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol. Sci.24, 471–478 (2003).
   PubMed Web of Science ®Google Scholar
• Walford G, Loscalzo J. Nitric oxide in vascular biology. J. Thromb. Haemost.1, 2112–2118 (2003).
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Vitamin C improves endothelium-dependent vasodilation by restoring nitric oxide activity in essential hypertension. Circulation97, 2222–2229 (1998).
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Ghiadoni L, Magagna A, Salvetti A. Cyclooxygenase inhibition restores nitric oxide activity in essential hypertension. Hypertension29, 274–279 (1997).
   PubMed Web of Science ®Google Scholar
• Cardillo C, Kilcoyne CM, Cannon RO III, Quyyumi AA, Panza JA. Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension30, 57–63 (1997).
   PubMed Web of Science ®Google Scholar
• Sherman DL, Keaney JF, Biegelsen ES, Duffy SJ, Coffman JD, Vita JA. Pharmacological concentrations of ascorbate acid are required for the beneficial effect on endothelial vasomotor function in hypertension. Hypertension35, 936–941 (2000).
   PubMed Web of Science ®Google Scholar
• Dröge W. Free radicals in the physiological control of cell function. Physiol. Rev.82, 47–95 (2001).
   Web of Science ®Google Scholar
• Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am. J. Cardiol.91(Suppl.), A7–A11 (2003).
   PubMed Web of Science ®Google Scholar
• Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine. Oxford University Press, Oxford, UK (1999).
   Google Scholar
• Griendling KK, Fitzgerald GA. Oxidative stress and cardiovascular injury. Part I: Basic mechanisms and in vivo monitoring of ROS. Circulation108, 1912–1916 (2003).
   PubMed Web of Science ®Google Scholar
• Palmer RMJ, Ferrige AG, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature333, 664–666 (1988).
   PubMed Web of Science ®Google Scholar
• Bredt DS, Snyder SH. Nitric oxide: a physiological messenger molecule.Ann. Rev. Biochem.63, 175–195 (1994).
   PubMed Web of Science ®Google Scholar
• Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet338, 1546–1550 (1991).
   PubMed Web of Science ®Google Scholar
• d’Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long-term Vitamin C treatment increases vascular tetrahydrobiopterin levels and nitric oxide synthase activity. Circ. Res.92, 88–95 (2003).
   PubMed Web of Science ®Google Scholar
• Stamler JS, Meissner G. Physiology of nitric oxide in skeletal muscle. Physiol. Rev.81, 209–237 (2001).
   PubMed Web of Science ®Google Scholar
• Rossi GP, Cesari M, Zanchetta M et al. The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patiens of the GENICA study. J. Am. Coll. Cardiol.41, 930–937 (2003).
   PubMed Web of Science ®Google Scholar
• Buga GM, Griscavage JN, Rogers NE, Ignarro LJ. Negative feedback regulation of endothelial cell function by nitric oxide. Circ. Res.73, 808–812 (1993).
   PubMed Web of Science ®Google Scholar
• Li H, Wallerath T, Munzel T, Forstermann U. Regulation of endothelial-type NO synthase expression in pathophysiology and in response to drugs. Nitric Oxide7, 149–164 (2002).
   PubMed Web of Science ®Google Scholar
• González-Santiago L, López-Ongil S, Rodríguez-Puyol M, Rodríguez-Puyol D. Decreased nitric oxide synthesis in human endothelial cells cultured on Type I collagen. Circ. Res.90, 539–545 (2002).
   PubMed Web of Science ®Google Scholar
• Fisslthalter B, Benzing T, Busse R, Fleming L. Insulin enhances the expression of the endothelial nitric oxide synthase in native endothelial cells: a dual role for Akt and AP-1. Nitric Oxide8, 253–261 (2003).
   PubMed Web of Science ®Google Scholar
• Inoue N, Venema RC, Sayegh HS, Ohara Y, Murphy TJ, Harrison DG. Molecular regulation of the bovine endothelial nitric oxide synthase by transforming growth factor-β1. Arterioscler. Thromb. Vasc. Biol.15, 1255–1261 (1995).
   PubMed Web of Science ®Google Scholar
• McQuillan LP, Leung GK, Marsden PA, Kostyk SK, Kourembanas S. Hypoxia inhibits expression of eNOS via transcriptional and posttranscriptional mechanisms. Am. J. Physiol.267, H1921–H1927 (1994).
   PubMed Web of Science ®Google Scholar
• Lamas S, Michel T, Brenner B, Marsden P. Nitric oxide synthesis in endothelial cells: evidence for a pathway inducible by tumor necrosis factor-α. Am. J. Physiol.261, C634–C641 (1991).
   Web of Science ®Google Scholar
• Liao JK, Shin WS, Lee WY, Clark SL. Oxidized low-density lipoprotein decreases the expression of endothelial nitric oxide synthase. J. Biol. Chem.270, 319–324 (1995).
   PubMed Web of Science ®Google Scholar
• Michel T, Li GK, Busconi L. Phosphorylation and subcellular translocation of endothelial nitric oxide synthase. Proc. Natl Acad. Sci. USA90, 6252–6256 (1993).
   PubMed Web of Science ®Google Scholar
• García-Cardeña G, Oh P, Liu J, Schnitzer JE, Sessa WC. Targeting of nitric oxide synthase to endothelial cell caveolae via palmitoylation: implication for nitric oxide signaling. Proc. Natl Acad. Sci. USA93, 6448–6453 (1996).
   PubMed Web of Science ®Google Scholar
• Walters JF, Skene DJ, Hampton SM, Ferns GAA. Biological rhythms, endothelial health and cardiovascular disease. Med. Sci. Monit.9, RA1–RA8 (2003).
   PubMed Web of Science ®Google Scholar
• Zhou Q, Hellerman G, Solomonson L. Nitric oxide release from resting human platelets. Thrombosis Res.77, 87–96 (1995).
   PubMed Web of Science ®Google Scholar
• Queen LR, Xu B, Horinouchi K, Fisher I, Ferro A. β(2)-adrenoceptors activate nitric oxide synthase in human platelets. Circ. Res.87, 39–44 (2000).
   PubMed Web of Science ®Google Scholar
• Freedman JE, Loscalzo J. Nitric oxide and its relationship to thrombotic disorders. J. Thromb. Heamost.1, 1183–1188 (2003).
   PubMed Web of Science ®Google Scholar
• García-Cardeña G, Fan R, Shah V et al. Dynamic activation of endothelial nitric oxide synthase by Hsp90. Nature392, 821–824 (1998).
   PubMed Web of Science ®Google Scholar
• Trochu JN, Bouhour JB, Kaley G, Hintze TH. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism. Implication in health and disease. Circ. Res.87, 1108–1117 (2000).
   PubMed Web of Science ®Google Scholar
• Edmunds NJ, Moncada S, Marshall JM. Does nitric oxide allow endothelial cells to sense hypoxia and mediate hypoxic vasodilatation? In vivo and in vitro studies. J. Physiol.546, 521–527 (2003).
   PubMed Web of Science ®Google Scholar
• Higashi Y, Sasaki S, Kurisu S et al. Regular aerobic exercise augments endothelium-dependent vascular relaxation in normotensive as well as hypertensive subjects. Circulation100, 1194–1202 (1999).
   PubMed Web of Science ®Google Scholar
• Taddei S, Galetta F, Virdis A et al. Physical activity prevents age-related impairment in nitric oxide availability in elderly athletes. Circulation101, 2896–2901 (2000).
   PubMed Web of Science ®Google Scholar
• Pu Q, Fitsch Neves M, Virdis A, Touyz RM, Schiffrin EL. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodelling. Hypertension42, 49–55 (2003).
   PubMed Web of Science ®Google Scholar
• Touyz RM, Schiffrin EL. Role of endothelin in human hypertension. Can. J. Physiol. Pharmacol.81, 533–541 (2003).
   PubMed Web of Science ®Google Scholar
• Li DY, Zhang YC, Philips MI, Sawamura T, Mehta JL. Upregulation of endothelial receptor for oxidized low-density lipoprotein (LOX-1) in cultured human coronary artery endothelial cells by angiotensin II Type 1 receptor activation. Circ. Res.84, 1043–1049 (1999).
   PubMed Web of Science ®Google Scholar
• Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the Angiotensin II Type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension35, 501–506 (2000).
   PubMed Web of Science ®Google Scholar
• Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am. J. Hypertens.16, 123–128 (2003).
   PubMed Web of Science ®Google Scholar
• Dallinger S, Sieder A, Strametz J, Bayerle-Eder M, Woltz M, Schmetterer L. Vasodilator effects of L-arginine are stereospecific and augmented by insulin in humans. Am. J. Physiol.284, E1106–E1111 (2003).
   Google Scholar
• Begum N. Insulin signalling in the vasculature. Front. Biosci.8, 796–804 (2003).
   Google Scholar
• Randriamboavonjy V, Schrader J, Busse R, Fleming I. Insulin induces the release of vasodilator compounds from platelets by a nitric oxide-G kinase-V AMP-3-dependent pathway. J. Exp. Med.199, 347–356 (2004).
   PubMed Web of Science ®Google Scholar
• Fukai T, Siegfried MR, Ushio-Fukai M, Cheng Y, Kojda G, Harrison DG. Regulation of the vascular extracellular superoxide dismutase by nitric oxide and exercise training. J. Clin. Invest.105, 1631–1639 (2000).
   PubMed Web of Science ®Google Scholar
• Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG. Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ. Res.86, 347–354 (2000).
   PubMed Web of Science ®Google Scholar
• Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, Gutterman DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ. Res.92, E31–E40 (2003).
   PubMed Web of Science ®Google Scholar
• Foster MW, McMahon TJ, Stamler JS. S-nitrosylation in health and disease. Trends Mol. Med.9, 160–168 (2003).
   PubMed Web of Science ®Google Scholar
• McMahon TJ, Moon RE, Luschinger BP et al. Nitric oxide in the human respiratory cycle. Nature Med.8, 711–717 (2002).
   PubMed Web of Science ®Google Scholar
• Pawloski JR, Hess DT, Stamler JS. Export by red blood cells of nitric oxide bioactivity. Nature409, 622–626 (2001).
   PubMed Web of Science ®Google Scholar
• May JM, Qu ZC, Morrow JD. Mechanisms of ascorbate acid recycling in human erythrocytes. Biochim. Biophys. Acta1528, 159–166 (2001).
   PubMed Web of Science ®Google Scholar
• May JM, Qu ZC, Neel DR, Li X. Recycling of vitamin C from its oxidized forms by human endothelial cells. Biochim. Biophys. Acta1640, 153–161 (2003).
   PubMed Web of Science ®Google Scholar
• Scorza G, Pietraforte D, Minetti M. Role of ascorbate and protein thiols in the release of nitric oxide from S-nitroso-albumin and S-nitroso-glutathione in human plasma. Free Rad. Biol. Med.22, 633–642 (1997).
   PubMed Web of Science ®Google Scholar
• Raghavan SA, Sharman P, Dikshit M. Role of ascorbate acid in the modulation of inhibition of platelet aggregation by polymorphonuclear leukocytes. Thromb. Res.110, 17–126 (2003).
   Google Scholar
• Cirillo M, Laurenzi M, Trevisan M, Stamler J. Hematocrit, blood pressure, and hypertension. The Gubbio Population Study. Hypertension20, 319–326 (1992).
   PubMed Web of Science ®Google Scholar
• Guimarães S, Moura D. Vascular adrenoceptors: an update. Pharmacol. Rev.53, 319–356 (2001).
   PubMed Web of Science ®Google Scholar
• Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: 10 years after, and continuing. Circ. Res.93, 388–398 (2003).
   PubMed Web of Science ®Google Scholar
• Hintze TH. Prologue: nitric oxide-hormones, metabolism, and function. Am. J. Physiol.281, H2253–H2255 (2001).
   Google Scholar
• Wassmann S, Laufs U, Bäumer AT et al. HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species. Hypertension37, 1450–1457 (2001).
   PubMed Web of Science ®Google Scholar
• Wagner AH, Köhler T, Rückschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol.20, 61–69 (2000).
   PubMed Web of Science ®Google Scholar
• Nickenig G, Bäumer AT, Temur Y, Kebben D, Jockenhövel F, Böhm M. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation100, 2131–2134 (1999).
   PubMed Web of Science ®Google Scholar
• Creager MA, Roddy MA. Effect of captopril and enalapril on endothelial function in hypertensive patients. Hypertension24, 499–505 (1994).
   PubMed Web of Science ®Google Scholar
• Kiowski W, Linder L, Nuesch R, Martina B. Effects of cilazapril on vascular structure and function in essential hypertension. Hypertension27, 371–376 (1996).
   PubMed Web of Science ®Google Scholar
• Iuchi T, Akaike M, Mitsui T et al. Glucocorticoid excess induces superoxide production in vascular endothelial cells and elicits vascular endothelial dysfunction. Circ. Res.92, 81–87 (2003).
   PubMed Web of Science ®Google Scholar
• Channon KM, Guzik TJ. Mechanisms of superoxid production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. J. Physiol. Pharmacol.53, 515–524 (2002).
   PubMed Web of Science ®Google Scholar
• Mitchell BM, Webb RC. Impaired vasodilation and nitric oxide synthase activity in glococorticoid-induced hypertension. Biol. Res. Nurs.4, 16–21 (2002).
   PubMedGoogle Scholar
• Li L, Fink GD, Watts SW et al. Endothelin-1 increases vascular superoxide via endothelin(A)-NADPH oxidase pathway in low-renin hypertension. Circulation107, 1053–1058 (2003).
   PubMed Web of Science ®Google Scholar
• Cosentino F, Eto M, De Paolis P et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation107, 1017–1023 (2003).
   PubMed Web of Science ®Google Scholar
• Benderdour M, Charron G, deBlois D, Comte B, Des Rosiers C. Cardiac mitochondrial NADP+-isocitrate dehydrogenase is inactivated through 4-hydroxynonenal adduct formation. J. Biol. Chem.278, 45154–45159 (2003).
   PubMed Web of Science ®Google Scholar
• Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite, tetrahydrobiopterin, ascorbate acid, and thiols: implications for uncoupling endothelial nitric oxide synthase. J. Biol. Chem.278, 22546–22554 (2003).
   PubMed Web of Science ®Google Scholar
• Stuher S, Puo S, Rosen GM. Oxygen reduction by nitric oxide synthases. J. Biol. Chem.276, 14533–14536 (2001).
   PubMed Web of Science ®Google Scholar
• Landmesser U, Dikalov S, Price SR et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial nitric oxide synthase in hypertension. J. Clin. Invest.111, 1201–1209 (2003).
   PubMed Web of Science ®Google Scholar
• d’Uscio LV, Milstien S, Richardson D, Smith L, Katusic ZS. Long-term vitamin C treatment increases vascular tatrahydrobiopterin levels and nitric oxide synthase activity. Circ. Res.92, 88–95 (2003).
   PubMed Web of Science ®Google Scholar
• Hofman H, Schmidt HH. Thiol dependence of nitric oxide synthase. Biochemistry34, 13443–13452 (1995).
   PubMed Web of Science ®Google Scholar
• Shokoji T, Nishiyama A, Fujisawa Y et al. Renal sympathetic nerve responses to Tempol in spontaneously hypertensive rats. Hypertension41, 266–273 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson P. Antioxidant enzyme expression in health and disease: effects of exercise and hypertension. Comp. Biochem. Physiol. Toxicol. Pharmacol.133, 493–505 (2002).
   PubMed Web of Science ®Google Scholar
• Leopold JA, Cap A, Scribner AW, Stanton RC, Loscalzo J. Glucose-6-phosphate dehydrogenase deficiency promotes endothelial oxidant stress and decreases endothelial nitric oxide availability. FASEB J.15, 1771–1773 (2001).
   PubMed Web of Science ®Google Scholar
• Redón J, Oliva MR, Tormos C et al. Antioxidant activities and oxidative stress by-products in human hypertension. Hypertension41, 1096–1101 (2003).
   PubMed Web of Science ®Google Scholar
• Johnson RJ, Kang DH, Feig D et al. Is there a pathogenic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension41, 1183–1190 (2003).
   PubMed Web of Science ®Google Scholar
• Piperno A, Trombini P, Gelosa M et al. Increased serum ferritin is common in men with essential hypertension. J. Hypertens.20, 1513–1518 (2002).
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int.53, 1748–1754 (1998).
   PubMed Web of Science ®Google Scholar
• Evans WJ. Vitamin E, vitamin C, and exercise. Am. J. Clin. Nutr.72(Suppl.), 647S–652S (2000).
   PubMed Web of Science ®Google Scholar
• Ohtahara A, Hisatome I, Yamamoto Y et al. The release of the substrate for xantine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and α1-blockers.J. Hypertens.19, 575–582 (2001).
   PubMed Web of Science ®Google Scholar
• Santangelo L, Cigliano L, Montefusco A et al. Evaluation of the antioxidant response in the plasma of healthy or hypertensive subjects after short-term exercise. J. Hum. Hypertens.17, 791–798 (2003).
   PubMed Web of Science ®Google Scholar
• Rachmani R, Levi Z, Zadok BS, Ravid M. Losartan and lercanidipine attenuate low-density lipoprotein oxidation in patients with hypertension and Type 2 diabetes mellitus: a randomized, prospective study. Clin. Pharmacol. Ther.72, 302–307 (2002).
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Ghiadoni et al. Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension. Hypertension37, 943–948 (2001).
   PubMed Web of Science ®Google Scholar
• Taddei S, Virdis A, Ghiadoni L et al. Calcium antagonist treatment by lercanidipine prevents hyperpolarization in essential hypertension. Hypertension41, 950–955 (2003).
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gréoire J, Lavoie MA, L’Allier PL. Vascular protectants for the treatment of atherosclerosis. Expert Rev. Cardovasc. Ther.1, 385–392 (2003).
   PubMedGoogle Scholar
• Salonen RM, Nyyssonen K, Kaikkonen J et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) study. Circulation107, 947–953 (2003).
   PubMed Web of Science ®Google Scholar
• Clarke R, Armitage J. Antioxidant vitamins and risk of cardiovascular disease. Review of large-scale randomized trials. Cardiovasc. Drugs Ther.16, 411–415 (2002).
   PubMed Web of Science ®Google Scholar
• Brown BG, Cheung MC, Lee AC, Zhao XQ, Chait A. Antioxidant vitamins and lipid therapy: end of a long romance? Arterioscler. Thromb. Vasc. Biol.22, 1535–1546 (2002).
   PubMed Web of Science ®Google Scholar
• Shihabi A, Li WG, Miller FJ Jr, Weintraub NL. Antioxidant therapy for atherosclerotic vascular disease: the promise and the pitfalls. Am. J. Physiol. Heart Circ. Physiol.282, H797–H802 (2002).
   Google Scholar
• Fink MP. Role of reactive oxygen and nitrogen species in acute respiratory distress syndrome. Curr. Opin. Crit. Care8, 6–11 (2002).
   PubMedGoogle Scholar
• Waeber B. Combination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertension. Expert Rev. Cardiovasc. Ther.1(1), 43–50 (2003).
   PubMedGoogle Scholar